Edwards Lifesciences Soars on TTVR Approval, But Challenges Remain

Edwards Lifescience (EW, Financial), a medical device company that specializes in cardiovascular, today by soaring 6% to $68.49 per share at the time this article was written. Technical analysis suggests that it's the moment of "strong buy". The market reacted after EW received its commercial approval of their transcatheter tricuspid valve replacement (TTVR) device thanks to their TRICSEND II trial that marks a significant milestone to the company. The TRISCEND II trial was a clinical study to evaluate the ...